"Parkinson Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
Descriptor ID |
D010300
|
MeSH Number(s) |
C10.228.140.079.862.500 C10.228.662.600.400 C10.574.812
|
Concept/Terms |
Parkinson Disease- Parkinson Disease
- Idiopathic Parkinson's Disease
- Lewy Body Parkinson Disease
- Lewy Body Parkinson's Disease
- Primary Parkinsonism
- Parkinsonism, Primary
- Parkinson Disease, Idiopathic
- Parkinson's Disease
- Parkinson's Disease, Idiopathic
- Parkinson's Disease, Lewy Body
- Idiopathic Parkinson Disease
- Paralysis Agitans
|
Below are MeSH descriptors whose meaning is more general than "Parkinson Disease".
Below are MeSH descriptors whose meaning is more specific than "Parkinson Disease".
This graph shows the total number of publications written about "Parkinson Disease" by people in this website by year, and whether "Parkinson Disease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 2 | 0 | 2 |
1996 | 1 | 0 | 1 |
1997 | 3 | 0 | 3 |
1998 | 3 | 0 | 3 |
1999 | 1 | 1 | 2 |
2000 | 2 | 1 | 3 |
2001 | 2 | 0 | 2 |
2002 | 5 | 1 | 6 |
2003 | 1 | 1 | 2 |
2004 | 0 | 1 | 1 |
2005 | 2 | 3 | 5 |
2006 | 4 | 1 | 5 |
2007 | 3 | 0 | 3 |
2008 | 0 | 1 | 1 |
2009 | 1 | 0 | 1 |
2010 | 5 | 1 | 6 |
2011 | 4 | 2 | 6 |
2012 | 3 | 0 | 3 |
2013 | 4 | 0 | 4 |
2014 | 4 | 1 | 5 |
2015 | 5 | 1 | 6 |
2016 | 2 | 0 | 2 |
2017 | 2 | 0 | 2 |
2018 | 3 | 0 | 3 |
2019 | 6 | 1 | 7 |
2020 | 2 | 0 | 2 |
2021 | 5 | 0 | 5 |
2022 | 5 | 0 | 5 |
2023 | 8 | 0 | 8 |
2024 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Parkinson Disease" by people in Profiles.
-
Risk of Common Neurological Disorders in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2024 Nov 04; 30(11):2195-2204.
-
The Black and African American Connections to Parkinson's Disease (BLAAC PD) study protocol. BMC Neurol. 2024 Oct 21; 24(1):403.
-
Parkinson's disease-associated mutations in a-synuclein alters its lipid-bound state. Biophys J. 2024 06 18; 123(12):1610-1619.
-
Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease". Mov Disord. 2024 Apr; 39(4):760-761.
-
Foreword for The Role of Gene Therapy in Sickle Cell Disease and Parkinson's Disease. Dis Mon. 2024 Jul; 70(7):101688.
-
Excess phosphoserine-129 a-synuclein induces synaptic vesicle trafficking and declustering defects at a vertebrate synapse. Mol Biol Cell. 2024 Jan 01; 35(1):ar10.
-
PARK7 Catalyzes Stereospecific Detoxification of Methylglyoxal Consistent with Glyoxalase and Not Deglycase Function. Biochemistry. 2023 11 07; 62(21):3126-3133.
-
miR-100a-5p-enriched exosomes derived from mesenchymal stem cells enhance the anti-oxidant effect in a Parkinson's disease model via regulation of Nox4/ROS/Nrf2 signaling. J Transl Med. 2023 10 24; 21(1):747.
-
A Dementia mortality rates dataset in Italy (2012-2019). Sci Data. 2023 08 25; 10(1):564.
-
Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study. Lancet Neurol. 2023 11; 22(11):1015-1025.